Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Living Cell faces slower road to commercialisation

Living Cell faces slower road to commercialisation after trial needs more

to editor
By Rebecca Howard

Nov. 10 (BusinessDesk) - ASX-listed Kiwi biotech firm Living Cell Technologies won't seek provisional consent for its treatment for Parkinson's disease after the latest trial did not show a "statistically significant difference" between people who received the treatment and those who didn't.

The Melbourne-based company halted trading of its shares yesterday ahead of the trial's results, which it was hoping would give it the all-clear to pursue commercial sales of its treatment as early as next year.

"More data analysis and input from our advisers is required but at this time we cannot proceed with a regulatory application," chief executive Ken Taylor said in a statement to the ASX.

Living Cell developed the NTCELL treatment for Parkinson’s disease using choroid plexus brain cells from neonatal pigs, which are implanted into a damaged site in the brain and then function as a “neurochemical factory” producing factors that promote new central nervous system growth and repair disease-induced nerve degeneration.

The cell therapy had shown potential in early trials as a disease-modifying agent in Parkinson’s disease. The latest study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient subgroup. The biotech firm's Phase IIb clinical trial was completed in April and it had been waiting for the results to be unblinded,

There were three groups of six patients and two patients from each group had sham surgery with no NTCELL implanted, to act as a control. The remaining patients received different numbers of microcapsules of NTCELL on each side of the brain.

While no product or procedure adverse events occurred and there is no evidence of xenogeneic infection in patients and their partners "we are disappointed that the efficacy primary endpoint has not been met," said Taylor.

Principal investigator Barry Snow at Auckland City Hospital said the next step is to analyse the data in depth and continue to monitor patients in accord with the study extension protocol, particularly for the efficacy movements at longer time points.

The ASX-listed shares last traded at 20.5 Australian cents and have risen 130 percent so far this year.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Talking Up The Economy: NZD Gains On PM's Mistaken GDP Comment

Her comments were downplayed by her chief press secretary who said she was referring the government's June year financial statements and had "made a mistake." More>>

ALSO:

Oxfam: Drug Companies Cheating Countries Out Of Billions In Tax

Oxfam’s analysis suggests these four companies are shifting profits out of countries where they do their business and into tax havens that charge little or no tax. More>>

Off The Lam: 50 Lambs Reported Lost, Found

The sheep had escaped and merged with another farmer’s flock. The combined flocks had been moved to another property before the farmer realised the missing sheep were included. More>>

Rotting Poles: Commission To File Proceedings Against Aurora Energy

The Commerce Commission has decided to file court proceedings against Dunedin-based electricity lines company Aurora Energy for breaching its regulated quality standards in 2016 and 2017. More>>

ALSO:

Gordon Campbell: On The Rising Cost Of Petrol

As petrol gets more and more expensive, Auckland motorists have several things to blame for it – the slumping value of the Kiwi dollar, Donald Trump’s sanctions on Iranian oil, hurricanes in the Caribbean… But it is simpler and feels better to lay all the blame on the regional fuel tax. More>>

ALSO: